Published in final edited form as:

Sleep Med. 2009 March ; 10(3): 277–278. doi:10.1016/j.sleep.2008.07.003.

Blue in the Face ¹

Michael Terman

Center for Light Treatment and Biological Rhythms, Columbia University Medical Center, 1051 Riverside Drive, Unit 50, New York, NY 10032 USA

Our understanding of retinal and circadian physiology has been profoundly transformed by the recent discovery that the ganglion cell pigment melanopsin – which had gone undetected in a century of photoreceptor research – responds to light and supports the phase-shifting mechanism of the body's master clock in the suprachiasmatic nucleus [1]. The effect is observable in animals lacking rods and cones, which would suggest that melanopsin mediates circadian rhythm entrainment exclusive of visual sensory input. Indeed, the action spectrum of melanopsin is distinct from the well-known rod and cone spectral sensitivity curves. It peaks in the short-wavelength “blue” range below 500 nm; the cone-mediated perception of blue is irrelevant. Beyond circadian entrainment, the spectral response of light-elicited pineal melatonin suppression also tracks the melanopsin curve [2]. Maybe we were wasting light energy all these years by shifting rhythms, suppressing melatonin and treating depression with longer wavelengths tuned to photopic sensory perception.

Light therapy is now widely used for the treatment of delayed sleep phase disorder and winter depression, and several other applications look promising - from nonseasonal depression to attention deficit/hyperactivity disorder to Parkinson's disease [3]. Light therapy apparatus is also a growing commercial industry without federal regulation. So it has not been surprising to see manufacturers quickly enter the market with clinical claims for melanopsin-tuned blue light apparatus, whether restricted to a short-wavelength narrow band of light or mixed with longer wavelengths for polychromatic presentation. All this without standard demonstrations of safety and specific efficacy.

The story actually long predates the discovery of melanopsin and its non-image-forming functions. The earliest light therapy studies (and commercial apparatus) used “full-spectrum” fluorescent light – an ill-defined quantity that boosts short-wavelength exposure. The choice of lamp – which was inspired by industry consultants to the National Institute of Mental Health – was not based on physiological data, but rather on the face-relevant assumption that outdoor skylight contains a lot of blue light and therefore should be good for you by comparison with indoor artificial light. There was also a suspicion that augmentation of ultraviolet (UV) radiation from these bulbs might enhance the response to light therapy. (One manufacturer installed a UV emitter in its light box.) Concern over the UV hazard quickly led to controlled clinical trials that blocked UV [4], and the need for blue-light augmentation was tested with lamps that attenuated short-wavelength emission [5]. The antidepressant response remained robust. Nevertheless, the aggressive marketing of full-spectrum light therapy continues. For one thing, the profit margin is higher than for conventional fluorescent lamps.

^K*Disclosure:* Dr. Terman was supported by the National Institutes of Health, New York State Office of Mental Health and the Center for Environmental Therapeutics.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

It has taken some time for data on the potential clinical benefits of short-wavelength exposure to appear. In a study of winter depression, bright narrow-band blue light was superior to dim red light [6]. Although this result may indicate a benefit relative to placebo, it does not demonstrate the specific efficacy of blue light. Nevertheless, this study motivated the first mass-market initiative for light therapy apparatus, using blue light-emitting diodes, with distribution including the Costco chain. Many clinicians, naïve to the issues, became enthusiasts. There was, however, concern in the ophthalmology community that such short-wavelength exposure could cause direct long-term damage to retinal structures, exacerbation of age-related macular degeneration, and a photosensitization hazard with common medications including certain psychotropic drugs [7]. The ubiquitous yellowing of the lens with age, which largely blocks short-wavelength transmission, might indeed serve a protective function. Counteracting this lens filter with massive doses of blue light in the elderly might be counterproductive. Regardless, the Food and Drug Administration declined a review.

As basic research proceeded, it became apparent that the melanopsin response in ganglion cells does not act in a vacuum. For example, the classical photoreceptors activate the same ganglion cells that subserve the melanopsin response [8]. Exposure to longer-wavelength light restores and enhances the short-wavelength melanopsin response [9]. At relatively low light intensities, and at the initiation of long-duration exposure to bright light, cone input predominates over melanopsin input in the suppression of melatonin [10].

Such results have been addressed with a compromise solution called “blue-enriched polychromatic [fluorescent] light” that maintains a broad spectrum, yet raises the color temperature from 3000-4000 Kelvin (conventional white fluorescent light) and 5500-7000 Kelvin (the “full spectrum” range, still white but with short-wavelength supplementation) to 17,000 Kelvin (distinctly bluish with heavy weighting toward short wavelengths). I find the term “blue-enriched” an implicit advertising claim for superiority over lower color temperatures. All three ranges of color temperature include short wavelengths and – if we look across studies – can effectively elicit circadian phase shifting, melatonin suppression and the antidepressant response. Theoretically – but not necessarily – 17,000 Kelvin might be more potent at lower levels of irradiance given melanopsin's spectral sensitivity. However, there are no comparative dose-response studies. Nevertheless, the commercial initiative is already intense (17,000 Kelvin ActiViva Active®, Philips Electronics N.V.), with “blue-enriched” bulbs more than twice the price of conventional fluorescents.

Two years ago, Marijke Gordijn and colleagues reported a controlled trial of 5000 and 17,000 Kelvin lamps at 10,000 lux for the treatment of winter depression [11]. They found no difference. To its credit, Philips summarizes the study on its website, including the authors' conclusion that the blue component of the 5000 Kelvin light might have been sufficient to saturate the melanopsin response.

In this issue of *Sleep Medicine*, Mark Smith and colleagues [12] take the comparisons an important step further with an examination of the circadian rhythm phase shifting potency of light exposure using 4100 Kelvin at 6000 lux and 17,000 Kelvin at 4000 lux, approximately matched for irradiance ($\sim 1700 \mu\text{W}/\text{cm}^2$). Their goal was to test the lamps as they might be used for the treatment of delayed sleep phase disorder or jet-lag adjustment in the real world where these lamps are marketed. In an elegant procedural refinement, early morning bright light exposures were scheduled according to each subject's baseline melatonin onset phase. Thus, the noisy data typical of studies that present light at a standardized clock time (vs. circadian time) were eliminated. With wake-up and light exposure moved one hour earlier daily for four days, the hypothesis that 17,000 Kelvin light would produce larger phase advances was not confirmed.

One reviewer actually called this study “scientifically meaningless” because it failed to identify the low irradiance threshold for phase shifting with the two lamps. The higher color temperature might win out at threshold. Yet consider the effort and expense of dose-response comparisons of phase shifting, melatonin suppression and antidepressant efficacy. It is probably not worth it. Fluorescent light is complicated by idiosyncratic spectral emission profiles based on particular phosphor combinations, superimposed by a discontinuous set of mercury spikes (roughly illustrated in Figure 2 [12]). This is not ideal for parametric investigation. Furthermore, these lamps will soon be replaced by technology that increases energy efficiency and reduces the toxic waste hazard.

I consider this study a major accomplishment and contribution to clinical practice. Patients do not use light therapy at the lowest threshold of effect. Rather, they seek maximum response at comfortable high doses that require minimal exposure duration. By assiduous methodology that approximates the application of light therapy, the study allows us to put exaggerated, commercially inspired claims in perspective, and question whether blue-light “enrichment” represents a major conceptual, technological or clinical advance.

References

1. Berson DM, Dunn FDA, Takao M. Phototransduction by retinal ganglion cells that set the circadian clock. *Science* 2002;295:1070–3. [PubMed: 11834835]
2. Brainard GC, Hanifin JP, Greeson JM, et al. Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor. *J Neurosci* 2001;21:6405–12. [PubMed: 11487664]
3. Terman M. Evolving applications of light therapy. *Sleep Med Rev* 2007;11:497–507. [PubMed: 17964200]
4. Lam RW, Buchanan A, Mador JA, et al. The effects of ultraviolet-A wavelengths in light therapy for seasonal depression. *J Affect Disord* 1992;24:237–43. [PubMed: 1578079]
5. Terman JS, Terman M, Schlager D, et al. Efficacy of brief, intense light exposure for treatment of winter depression. *Psychopharmacol Bull* 1990;26:3–11. [PubMed: 2371371]
6. Glickman G, Byrne B, Pineda C, et al. Light therapy for seasonal affective disorder with blue narrow-band light-emitting diodes (LEDs). *Biol Psychiatry* 2006;59:502–7. [PubMed: 16165105]
7. Center for Environmental Therapeutics. Cautionary notes about bright light exposure. [21 July 2008]. www.cet.org.
8. Aggelopoulos NC, Meissl H. Responses of neurons of the rat suprachiasmatic nucleus to retinal illumination under photopic and scotopic conditions. *J Physiol* 2000;523:211–22. [PubMed: 10673556]
9. Mure LS, Rieux C, Hattar S, Cooper HM. Melanopsin-dependent nonvisual responses: evidence for photopigment bistability in vivo. *J Biol Rhythms* 2007;22:411–24. [PubMed: 17876062]
10. Gooley JJ, Rajaratnam SMW, Brainard GC, et al. The spectral sensitivity of human circadian photoreception is dynamic and changes depending on the irradiance and duration of light. *Soc Res Biol Rhythms Abstr* 2008;11:94.
11. Gordijn MCM, Manneetje D, Meesters Y. The effects of blue enriched light treatment compared to standard light treatment in SAD. *Soc Light Treatment Biol Rhythms Abstr* 2006;18:000.page number pending from author
12. Smith MR, Revell VL, Eastman CI. Phase advancing the human circadian clock with blue-enriched polychromatic light. *Sleep Med* 2008;00:000–000.volume/page numbers pending from Editor